Performance of KROS Keros Therapeutics Inc | 43.8% in 12m
Compare KROS with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Keros Therapeutics Inc with its related Sector/Index XBI
Performance Duell KROS vs XBI
| TimeFrame | KROS | XBI |
|---|---|---|
| 1 Week | 15.8% | -4.68% |
| 1 Month | 7.69% | 2.20% |
| 3 Months | 7.85% | 4.12% |
| 6 Months | -20.4% | -3.48% |
| 12 Months | 43.8% | 22.61% |
| YTD | 21.8% | 7.10% |
| Rel. Perf. 1m | 0.62 | |
| Rel. Perf. 3m | -2.26 | |
| Rel. Perf. 6m | -2.69 | |
| Rel. Perf. 12m | -2.69 | |
| Spearman 1m | 0.57 | 0.47 |
| Spearman 3m | 0.07 | 0.70 |
Is Keros Therapeutics Inc a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Keros Therapeutics Inc (NASDAQ:KROS) is currently (September 2024)
ok to buy, but has to be watched. It has a Growth Technical Rating of 39.79 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KROS as of September 2024 is 48.49. This means that KROS is currently overvalued and has a potential downside of -7.66% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KROS as of September 2024 is 48.49. This means that KROS is currently overvalued and has a potential downside of -7.66% (Sold with Premium).
Is KROS a buy, sell or hold?
- Strong Buy: 8
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: KROS is performing better - Values below 0%: KROS is underperforming
Compare KROS with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 19.93% | 4.20% | -27.05% | 21.64% |
| US NASDAQ 100 | QQQ | 21.58% | 5.61% | -22.92% | 23.97% |
| US Dow Jones Industrial 30 | DIA | 18.61% | 3.89% | -25.67% | 25.32% |
| German DAX 40 | DBXD | 19.03% | 2.29% | -23.20% | 29.22% |
| UK FTSE 100 | ISFU | 18.04% | 1.42% | -32.69% | 25.66% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 18.47% | 10.00% | -14.10% | 54.73% |
| Hongkong Hang Seng | HSI | 18.01% | 2.92% | -20.88% | 49.66% |
| Japan Nikkei 225 | EXX7 | 22.91% | 2.01% | -10.24% | 37.96% |
| India NIFTY 50 | INDA | 17.89% | 5.08% | -28.81% | 19.51% |
| Brasil Bovespa | EWZ | 17.50% | 0.81% | -11.86% | 43.58% |
KROS Keros Therapeutics Inc vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 19.86% | 7.10% | -27.74% | 19.30% |
| Consumer Discretionary | XLY | 18.31% | 2.30% | -22.36% | 37.73% |
| Consumer Staples | XLP | 15.21% | 1.62% | -32.19% | 25.67% |
| Energy | XLE | 21.56% | 8.81% | -20.69% | 45.96% |
| Financial | XLF | 18.96% | 0.97% | -30.27% | 13.08% |
| Health Care | XLV | 17.86% | 3.32% | -26.60% | 26.17% |
| Industrial | XLI | 20.03% | 4.54% | -24.58% | 22.75% |
| Materials | XLB | 20.45% | 6.10% | -22.47% | 32.17% |
| Real Estate | XLRE | 15.61% | 2.68% | -32.14% | 20.45% |
| Technology | XLK | 23.24% | 6.03% | -19.12% | 25.50% |
| Utilities | XLU | 16.29% | 3.52% | -42.49% | 20.06% |
| Aerospace & Defense | XAR | 21.00% | 3.69% | -24.84% | 17.48% |
| Biotech | XBI | 20.47% | 5.49% | -16.89% | 21.21% |
| Homebuilder | XHB | 20.19% | 4.27% | -28.21% | 6.22% |
| Retail | XRT | 20.77% | 8.20% | -17.12% | 25.17% |
Does Keros Therapeutics Inc outperform its market, is KROS a Sector Leader?
Yes, over the last 12 months Keros Therapeutics Inc (KROS) made 43.82%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months KROS made 7.85%, while XBI made 4.12%.
Yes, over the last 12 months Keros Therapeutics Inc (KROS) made 43.82%, while its related Sector, the SPDR S&P Biotech (XBI) made 22.61%.
Over the last 3 months KROS made 7.85%, while XBI made 4.12%.
| Period | KROS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 7.69% | 2.20% | 3.49% |
| 3 Months | 7.85% | 4.12% | 1.39% |
| 12 Months | 43.82% | 22.61% | 22.18% |